How should I initiate and titrate GLP‑1 receptor agonist therapy (e.g., semaglutide, liraglutide, dulaglutide) in an adult with type 2 diabetes or obesity who has no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and what monitoring is required?

GLP-1 Receptor Agonist Initiation and Titration

Start with semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily as first-line GLP-1 RA therapy in adults with type 2 diabetes or obesity, using slow dose escalation over 4-8 weeks to minimize gastrointestinal side effects. 1, 2

Patient Selection

Appropriate candidates:

• Adults with type 2 diabetes not at glycemic goal on metformin alone 3, 4
• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications 1, 2
• Patients with established cardiovascular disease or multiple CV risk factors 3, 5
• Patients with chronic kidney disease (eGFR ≥30 mL/min/1.73 m²) 3

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma 6, 7, 8
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 6, 7, 8
• Serious hypersensitivity to the specific GLP-1 RA 6, 7, 8
• Pregnancy or breastfeeding 3

Use caution in:

• Severe renal impairment (eGFR <30 mL/min/1.73 m²) - not recommended for exenatide or lixisenatide 3
• History of pancreatitis - consider alternative therapies 3, 4
• Severe gastroparesis or prior gastric/bariatric surgery 3

Specific Dosing Protocols

Semaglutide (Subcutaneous)

Start at 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg weekly. If additional glycemic control needed after at least 4 weeks, increase to 1 mg weekly. For obesity indication, can escalate to 2.4 mg weekly using monthly increases (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg). 8, 9

• Administer any day of the week, any time of day, with or without food 8
• Inject subcutaneously in abdomen, thigh, or upper arm 8
• If dose missed, administer within 5 days; otherwise skip and resume regular schedule 8

Liraglutide

Start at 0.6 mg once daily for at least 1 week, then increase to 1.2 mg daily. If additional control needed after 1 week, increase to maximum 1.8 mg daily (for diabetes) or 3.0 mg daily (for obesity). 7, 9

• Administer once daily at any time, independent of meals 7
• Inject subcutaneously in abdomen, thigh, or upper arm 7

Dulaglutide

Start at 0.75 mg once weekly, increase to 1.5 mg weekly after 4 weeks if needed. For additional glycemic control, can escalate in 1.5 mg increments every 4 weeks to maximum 4.5 mg weekly. 6

• Administer once weekly, any time of day, with or without food 6

Critical Monitoring Requirements

Gastrointestinal tolerability:

• Nausea, vomiting, and diarrhea occur in 25-40% of patients 10, 11
• Peak during dose escalation, typically resolve within 4-8 weeks 10
• Manage with smaller meals, adequate hydration, avoiding high-fat foods 10

Hypoglycemia risk:

• Minimal when used as monotherapy 3, 4
• Reduce insulin secretagogue (sulfonylurea) or insulin doses by 20-30% when initiating GLP-1 RA to prevent hypoglycemia 3, 12

Renal function:

• Monitor in patients with baseline renal impairment, especially if severe GI adverse events occur 7, 8
• Dehydration from vomiting/diarrhea can precipitate acute kidney injury 7

Diabetic retinopathy:

• Monitor patients with history of diabetic retinopathy, particularly with rapid glycemic improvement 3, 8
• Semaglutide showed increased retinopathy complications in SUSTAIN-6 trial 3

Gallbladder disease:

• Obtain gallbladder studies if cholelithiasis or cholecystitis suspected 10, 2
• Increased risk with all GLP-1 RAs 2

Pancreatitis:

• Discontinue immediately if suspected; do not restart if confirmed 3, 6, 7, 8
• Though causality remains uncertain, use caution in those with prior pancreatitis 4, 11

Choosing Between Agents

Prioritize semaglutide 2.4 mg weekly for most patients given superior weight loss (15-17% vs 8% with liraglutide) and once-weekly dosing improving adherence. 1, 9

Choose liraglutide 3.0 mg daily when:

• Cost/insurance coverage favors liraglutide 1
• Patient prefers daily dosing for flexibility 9
• Established cardiovascular disease present (LEADER trial showed CV benefit) 10, 9

Choose dulaglutide when:

• Simpler titration preferred (fewer dose adjustments) 6
• Once-weekly dosing desired with lower GI side effect profile 4

Common Pitfalls to Avoid

Do not escalate doses too rapidly - this is the primary cause of treatment discontinuation due to intolerable nausea. Maintain each dose for minimum 4 weeks. 3, 10, 2

Do not discontinue prematurely for GI side effects - most resolve within 4-8 weeks. Counsel patients upfront about expected nausea and management strategies. 10, 12

Do not forget to reduce concomitant insulin or sulfonylurea doses - failure to do so results in unnecessary hypoglycemia and treatment abandonment. 3, 12

Do not use in patients with gastroparesis - delayed gastric emptying is a mechanism of action and will worsen symptoms. 3

Do not assume all GLP-1 RAs have proven cardiovascular benefit - only liraglutide and semaglutide have demonstrated MACE reduction in cardiovascular outcomes trials. 10, 1, 9

Drug Interactions

Oral medications: GLP-1 RAs delay gastric emptying, potentially reducing absorption of oral medications. 6, 7, 8 For oral semaglutide specifically, take on empty stomach with ≤4 oz water, wait 30 minutes before other medications or food. 13

Real-World Adherence Considerations

Only 58% of patients reach recommended maintenance doses of semaglutide after 4 weeks in UK primary care, with 41% discontinuing within 1 year. 14 Persistence improves with:

• Thorough patient education about expected side effects and their transient nature 12
• Flexible dosing schedules aligned with patient lifestyle 14, 15
• Regular follow-up during titration phase 12
• Setting realistic weight loss expectations (5-10% for most agents, 15-20% for semaglutide 2.4 mg) 1, 9